Picture of UK Houses of Parliament

Leading national thinking on politics, government & public policy through Open Access research

Strathprints makes available scholarly Open Access content by researchers in the School of Government & Public Policy, based within the Faculty of Humanities & Social Sciences.

Research here is 1st in Scotland for research intensity and spans a wide range of domains. The Department of Politics demonstrates expertise in understanding parties, elections and public opinion, with additional emphases on political economy, institutions and international relations. This international angle is reflected in the European Policies Research Centre (EPRC) which conducts comparative research on public policy. Meanwhile, the Centre for Energy Policy provides independent expertise on energy, working across multidisciplinary groups to shape policy for a low carbon economy.

Explore the Open Access research of the School of Government & Public Policy. Or explore all of Strathclyde's Open Access research...

Strathprints

Audit of budesonide/formoterol prescribing for asthma in community pharmacy in the U.K

Boyter, Anne C and Ford, Naomi H and Zlotos, Leon (2011) Audit of budesonide/formoterol prescribing for asthma in community pharmacy in the U.K. Respiratory Medicine, 105 (6). pp. 864-868.

Full text not available in this repository.Request a copy from the Strathclyde author

Abstract

The rapid action of the long acting beta agonist formoterol allows it to be used as both a preventer and reliever in the management of asthma. The Symbicort® SMART dosing regime has been shown to reduce the number of asthma exacerbations. The aim was to determine the current prescribing of Symbicort®, the prescribing of the SMART regimen and the co-prescribing of a short acting beta agonist with this regimen by means of an audit of prescriptions dispensed in a pharmacy multiple in the U.K. Anonymised data were collected on a standard form. Symbicort® prescribing data for six months were extracted from the pharmacy Patient Medication Record (PMR). Data were stratified by age and analysed to determine adherence with Symbicort® SMART prescribing as defined by the U.K. product license. Data were received from 51 of the 118 (43.2%) pharmacies contacted. Complete information from 2484 PMRs was included in the study. 2.81% (70/2484) of patients were prescribed SMART as defined by the U.K. summary of product characteristics. Of the 18-35 year age group 7.44% (27/363) were prescribed SMART correctly. However, Symbicort® was prescribed twice a day and when required, with either the co-prescription of a SABA, or at an unlicensed dose in 2.46% (61/2484) and 0.28% (7/2484) patients respectively. The incidence of Symbicort® SMART prescribing in this study is low but may be underestimated due to unclear dosing instructions.

Item type:Article
ID code:32468
Notes:Copyright © 2010 Elsevier Ltd. All rights reserved.
Keywords:adolescent, adrenal cortex hormones, adult, aged, asthma, budesonide, child, cost-benefit analysis, drug combinations, drug therapy combination, ethanolamines, female, Great Britain, humans, male, medical audit, middle aged, pharmacies, young adult, Pharmacy and materia medica, Pulmonary and Respiratory Medicine
Subjects:Medicine > Pharmacy and materia medica
Department:Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Depositing user: Pure Administrator
Date deposited:09 Aug 2011 10:50
Last modified:03 Jan 2019 13:00
Related URLs:
URI:https://strathprints.strath.ac.uk/id/eprint/32468
Export data:
CORE (COnnecting REpositories)